Jun 12, 2021
October 17, 2022
December 20, 2021
October 29, 2021
May 7, 2021
August 9, 2019
Both transcranial magnetic stimulation (TMS) and infused ketamine are recognized treatments for patients suffering from major depressive disorder (MDD). A novel therapy named combination TMS with ketamine (CTK) is introduced. This retrospective review examined the safety and clinical benefits of CTK in patients suffering from treatment-resistant depression (TRD) during the routine practice of psychiatry in a private setting.
March 18, 2019
March 13, 2019
January 8, 2019
August 2, 2018
Open-label transcranial magnetic stimulation (TMS) reduced suicidal ideation in adolescents with treatment-resistant depression, according to the results of a study published in the Journal of Affective Disorders.
Suicide is a leading cause of death among adolescents worldwide.
In the United States, nearly 20% of adolescents [KL1] consider suicide, 15% have formulated plans for suicide, and almost 10% attempt suicide annually. Despite efforts to reduce suicide, the rate of suicide attempts and successful suicide continues to increase in the United States. Early attempts also predict similar behavior in adulthood.
July 17, 2018
September 9, 2021
December 22, 2021
January 17, 2018
April 20, 2017
October 1, 2012
May 2, 2018
A study published in the Journal of Affective Disorders demonstrated the cognitive safety of H1-coil transcranial magnetic stimulation (TMS) treatment for individuals with bipolar depression.
The exploratory study sought to evaluate the effects of H1-coil TMS treatment on 6 cognitive domains (attention and processing speed, inhibitory control, working memory and executive function, language, immediate verbal memory, and long-term verbal memory) in subjects with bipolar depression.
April 6, 2019
May 15, 2019
Magnetic stimulation of the brain improves working memory, offering a new potential avenue of therapy for individuals living with Alzheimer’s disease and other forms of dementia, according to a study published in PloS One.
In the study, healthy younger and older adult participants who received repetitive transcranial magnetic stimulation (rTMS) performed better on a memory task than during an rTMS-like placebo.
April 16, 2018
Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive treatment approved by the U.S. Food and Drug Administration for the treatment of clinical depression. The treatment is also being studied as a potential therapy for Alzheimer’s disease.
How rTMS works:
Alzheimer’s disease is the most common cause of dementia, affecting millions of mostly elderly people around the world. In these people, the synaptic activity (connections between nerve cells) collapses and brain networks gradually falter, resulting in a decline in memory and the ability to think and learn.
August 22, 2018
The US Food and Drug Administration (FDA) has approved a new magnetic stimulation device that is designed to treat patients with treatment-resistant major depressive disorder (MDD) in just 3 minutes.
The Express Transcranial Magnetic Stimulation (TMS) device, from MagVenture, has been approved by the FDA—expediting the treatment session speed set only by the company’s preceding TMS device when it was first cleared in 2008. What was once a treatment regimen that required patients with MDD to undergo a 30-minute-plus session 20-30 times, is now capable of being completed in just 3 minutes per session.
May 3, 2018
Intermittent theta burst stimulation, a shorter version of the 37-minute repetitive transcranial magnetic stimulation that can be delivered in 3 minutes, was noninferior to the longer version for treatment-resistant depression, findings published in The Lancet revealed.
“Several pilot trials and two meta-analyses indicate that [intermittent theta burst stimulation] is superior to sham treatment for treatment-resistant depression. However, the key practical question is whether [intermittent theta burst stimulation] performs comparably to the existing standard of care,” Daniel M. Blumberger, MD,of the department of psychiatry, University of Toronto, and colleagues wrote.
May 1, 2018
TORONTO, April 26, 2018 – In the largest study of its kind, a three-minute version of a brain stimulation treatment was shown to be just as effective as the standard 37-minute version for hard-to-treat depression.
These results were published in a new Canadian study in The Lancet co-led by the Centre for Addiction and Mental Health (CAMH) and the University Health Network’s Krembil Research Institute, in collaboration with the University of British Columbia.
The treatment is called repetitive transcranial magnetic stimulation (rTMS), which is a form of treatment that uses magnetic field pulses to non-invasively stimulate a part of the brain called the dorsolateral prefrontal cortex, which is associated with mood regulation. The study compared standard rTMS treatment, which uses high frequency (10 Hz) brain stimulation for 37.5 minutes per session, with a newer form of rTMS called intermittent theta burst stimulation (iTBS), that mimics the brain’s natural rhythms and takes just over three minutes per treatment.